Using cells from an unrelated donor

Mesoblast and its United States-based sister company, Angioblast Systems Inc., have commenced Phase 2 clinical trials in the United States examining the safety and efficacy of allogeneic (derived from universal donors and used in unrelated recipients) Mesenchymal Precursor Cells.

Both companies intend to commercialise 'off-the-shelf' products available for immediate use where speed is critical, such as for patients with compound fractures or heart attacks.

Off-the-shelf products have the commercial advantages of reducing the cost of goods sold as a result of economies of scale and present an attractive option for partnering with international pharmaceutical companies.


Product Development




 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine